Skip to main content
SpringerLink
Log in

Hepatozelluläres Karzinom

  • Chapter
Therapiekonzepte Onkologie

Zusammenfassung

90% primär maligner Lebertumoren sind hepatozelluläre Karzinome (HCC); in den übrigen Fällen handelt es sich meist um Cholangiokarzinome, Hepatoblastome (Kinder) und Sarkome. 60–80% der HCC sind mit einer Zirrhose assoziiert, in der westlichen Welt meist infolge eines Alkoholabusus. Die fibrolamelläre Variante des HCC ist meist nicht mit einer Zirrhose oder Hepatitis-B-Infektion assoziiert. Fernmetastasen finden sich am häufigsten in Lunge und Knochen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Cook CG, Moosa B (1985) Hepatocelular carcinoma: one of the world’s most common malignancies. Am J Med 233: 705–708

    Google Scholar 

  2. Lotze MT, Flickinger JC, Carr BI (1993) Hepatobiliary neoplasms. In: Cancer, Principles and Practice of Oncology. DeVita VT Jr, Hellmann S, Rosenberg SA (eds). 4th edition, JB Lippincott Co. Philadelphia, p 883–914

    Google Scholar 

  3. Lim RC, Bongard FS (1984) Hepatocellular carcinoma — changing concepts in diagnosis and management. Arch Surg 119: 637–642

    Article  PubMed  Google Scholar 

  4. Yumoto Y, Umeda M, Oshima K et al. (1994) Estimation of remnant liver function before hepatectomy by means of technetium-99m-diethylenetriamine-pentaacetic acid galactosyl human albumin. Cancer Chemother Pharmacol 33: S1 - S6

    Article  PubMed  Google Scholar 

  5. Ringe B, Pichlmayer R, Wittekind C, Tusch G (1991) Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients: World J Surg 15: 270–285

    PubMed  CAS  Google Scholar 

  6. Nagorney DM, Van Heerden JA, Illstrup DM, Adson MA (1989) Primary hepatic malignancy: surgical management and determinants of survival. Surgery 106: 740–749

    PubMed  CAS  Google Scholar 

  7. Okuda K, Ohstuki T, Obata H et al. (1985) Natural history of hepatocellular carcinoma and prognosis in relation to treatment: study of 850 patients. Cancer 56: 918–928

    Article  PubMed  CAS  Google Scholar 

  8. Yamanaka N, Okamoto E, Foyosaka A et al. (1990) Prognostic factors after hepatectomy for hepatocellular carcinoma. Cancer 65: 1104–1110

    Article  PubMed  CAS  Google Scholar 

  9. Nagasue N, Yukaya H, Ogawa Y, Sasaki Y, Chang YC, Niimi K (1986) Second hepatic resection for recurrent hepatocellular carcinoma. Br J Surg 73: 434–438

    Article  PubMed  CAS  Google Scholar 

  10. Iwatsuki S, Starzl TE, Sheahan DA et al. (1991) Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg 214: 221–229

    Article  PubMed  CAS  Google Scholar 

  11. Langer B, Greig PD, Taylor BR (1994) Surgical resection and transplantation for hepatocellular carcinoma. In: Hepatobiliary Cancer. Sugarbaker PH (ed). Kluwer Academic Publishers Boston, p 231–240

    Chapter  Google Scholar 

  12. Nerenstone SR, Ihde DC, Friedman MA (1988) Clinical trials in primary hepatocellular carcinoma: current status and future directions. Cancer Treat Rev 15: 1–31

    Article  PubMed  CAS  Google Scholar 

  13. Venook AP (1994) Treatment of hepatocellular carcinoma: too many options? J Clin Oncol 12: 1323–1334

    PubMed  CAS  Google Scholar 

  14. Patt YZ, Charnsangavej C, Yoffe B et al. (1994) Hepatic arterial infusion of floxuridine, leucovorin doxorubicin, and cisplatin for hepatocellular carcinoma: effects of hepatitis B and C viral infection on drug toxicity and patient survival. J Clin Oncol 12: 1204–1211

    PubMed  CAS  Google Scholar 

  15. Stone MJ, Klintmalm G, Polter D, Husberg B, Egorin MJ (1989) Neoadjuvant chemotherapy and orthotopic liver transplantation for hepatocellular carcinoma. Transplantation 48: 344–347

    Article  PubMed  CAS  Google Scholar 

  16. Carr BI, Selby R, Madariaga J, Iwatsuki S, Starzl TE (1993) Prolonged survival after liver transplantation and cancer chemotherapy for advanced-stage hepatocellular carcinoma. Transplant Proc 25: 1128–1129

    PubMed  CAS  Google Scholar 

  17. Ohnishi K, Tsuchiya S, Nakayama T et al. (1984) Arterial chemoembolization of hepatocellular carcinoma with mitomycin C microcapsules. Radiology 152: 51–55

    PubMed  CAS  Google Scholar 

  18. Kobayashi H, Hidaka H, Kajiya Y et al. (1986) Treatment of hepatocellular carcinoma by transarterial injection of anticancer agents in iodized oil suspension or of radioactive iodized oil solution. Acta Radiol Diagn 27: 139–147

    CAS  Google Scholar 

  19. Ohnishi K, Sugita S, Nomura F, Iida S, Tanabe Y (1987) Arterial chemoembolization with mitomycin C microcapsules followed by transcatheter hepatic artery embolization for hepatocellular carcinoma. Am J Gastroenterol 82: 876–879

    PubMed  CAS  Google Scholar 

  20. Sasaki Y, Imaoka S, Kasugai H et al. (1987) A new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin, and gelatin sponge. Cancer 60: 1194–1203

    Article  PubMed  CAS  Google Scholar 

  21. Lin DY, Liaw YF, Lee TY, Lai CM (1988) Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma — a randomized controlled trial. Gastroenterology 94: 453–456

    PubMed  CAS  Google Scholar 

  22. Kasugai H, Kojima J, Tatsuta M et al. (1989) Treatment of hepatocellular carcinoma by transcatheter arterial embolization combined with intraarterial infusion of a mixture of cisplatin and ethiodidzed oil. Gastroenterology 97:965–971

    Google Scholar 

  23. Kanematsu T, Furuta T, Takenaka K et al. (1989) A 5-year experience of lipiodolization: selective regional chemotherapy for 200 patients with hepatocellular carcinoma. Hepatology 10: 98–102

    Article  PubMed  CAS  Google Scholar 

  24. Shibata J, Fujiyama S, Sata T et al. (1989) Hepatic arterial injection chemotherapy with cisplatin suspended in an oily lymphographic agent for hepatocellular carcinoma. Cancer 64: 1586–1594

    Article  PubMed  CAS  Google Scholar 

  25. Venook AP, Stagg RJ, Lewis BJ et al. (1990) Chemoembolization for hepatocellular carcinoma. J Clin Oncol 8: 1108–1114

    PubMed  CAS  Google Scholar 

  26. Beppu T, Ohara C, Yamaguchi Y et al. (1991) A new approach to chemoembolization for unresectable hepatocellular carcinoma using aclarubicin microspheres in combination with cisplatin suspended in iodized oil. Cancer 68: 2555–2560

    Article  PubMed  CAS  Google Scholar 

  27. Stuart K, Stokes K, Jenkins R, Trey C, Clouse M (1993) Treatment of hepatocellular carcinoma using doxorubicin/ethiodized oil/gelatin powder chemoembolization. Cancer 72: 3202–3209

    Article  PubMed  CAS  Google Scholar 

  28. Yamada T, Makita F, Takehara K et al. (1994) Evaluation of the therapeutic effect of TAE on primary liver cancer. Cancer Chemother Pharmacol 33: S55 – S59

    Article  PubMed  Google Scholar 

  29. Nishimine K, Uchida H, Matsuo N et al. (1994) Segmental transarterial chemoembolization with Lipiodol mixed with anticancer drugs for nonresectable hepatocellular carcinoma: follow-up CT and therapeutic results. Cancer Chemother Pharmacol 33: S60 – S68

    Article  PubMed  Google Scholar 

  30. Yodono H, Takekawa SD, Tarusawa K et al. (1994) Combination therapy consisting of arterial infusion chemotherapy (EPF, EAP) and transcatheter arterial embolization (TAE). Cancer Chemother Pharmacol 33: S70 – S83

    Article  Google Scholar 

  31. Matsui O, Kadoya M, Yoshikawa J, Gabata T, Takashima T, Demachi H (1994) Subsegmental transcatheter arterial embolization for small hepatocellular carcinomas: local therapeutic effect and 5-year survival rate. Cancer Chemother Pharmacol 33: S84 – S88

    Article  PubMed  Google Scholar 

  32. Nakamura H, Mitani T, Murakami T et al. (1994) Five-year surival after trans-catheter chemoembolization for hepatocellular carcinoma. Cancer Chemother Pharmacol 33: S89 – S92

    Article  PubMed  Google Scholar 

  33. Kawai S, Tani M, Okamura J et al. (1994) Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma — a comparison between L-TAE with farmorubicin and L-TAE with adriamycin: preliminary results (second cooperative study). Cancer Chemother Pharmacol 33: 597–5102

    Google Scholar 

  34. Bronowocki JP, Vetter D, Dumas F et al. (1994) Transcatheter oily chemoembolization for hepatocellular carcinoma. A 4-year study of 127 French patients. Cancer 74: 16–24

    Article  Google Scholar 

  35. Shiina S, Tagawa K, Unuma T et al. (1990) Percutaneous ethanol injection therapy of hepatocellular carcinoma: analysis of 77 patients. AJR 155: 1221–1226

    Article  PubMed  CAS  Google Scholar 

  36. Livraghi T, Bolondi L, Lazzarani S et al. (1992) Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis. A study on 207 patients. Cancer 69: 925–929

    CAS  Google Scholar 

  37. Horiguchi Y, Sekoguchi B, Imai H et al. (1994) Treatment of choice for unresectable small liver cancer: percutaneous ethanol injection therapy or transarterial chemoembolization therapy. Cancer Chemother Pharmacol 33: 5111–5114

    Article  Google Scholar 

  38. Kato T, Saito Y, Niwa M, Ishiguro J, Ogoshi K (1994) Combination therapy of transcatheter chemoembolization and percutaneous ethanol injection therapy for unresectable hepatocellular carcinoma. Cancer Chemother Pharmacol 33: S115 — S118

    Article  PubMed  Google Scholar 

  39. Tateishi H, Kinuta M, Furukawa J et al. (1994) Follow-up study of combination treatment (TAE and PEIT) for unresectable hepatocellular carcinoma. Cancer Chemother Pharmacol 33: S119 – S123

    Article  PubMed  Google Scholar 

  40. Farinati F, Salvagnini M, De Maria N et al. (1990) Unresectable hepatocellular carcinoma: a prospective controlled trial with tamoxifen. J Hepatol 11: 297–301

    Article  PubMed  CAS  Google Scholar 

  41. Engstrom PF, Levin B, Moertel CG, Schott A (1990) A phase II trial of tamoxifen in hepatocellular carcinoma. Cancer 65: 2641–2643

    Article  PubMed  CAS  Google Scholar 

  42. Gupta S, Lorula J (1988) Failure of ketoconazole as anti-androgen therapy in nonresectable hepatocellular carcinoma. J Clin Gastroenterol 10: 651–654

    Article  PubMed  CAS  Google Scholar 

  43. Lai CL, Wu PC, Lok ASF et al. (1989) Recombinant a2-interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial. Br J Cancer 60: 928–933

    Article  PubMed  CAS  Google Scholar 

  44. Lai CL, Lau JYN, Wu PC et al. (1993) Recombinant interferon-a in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology 17: 389–394

    Article  PubMed  CAS  Google Scholar 

  45. Colleoni M, Buzzoni R, Bajetta E et al. (1993) A phase II study of motoxantrone combined with beta-interferon in unresectable hepatocellular carcinoma. Cancer 72: 3196–3201

    Article  PubMed  CAS  Google Scholar 

  46. Kardinal CG, Moertel CG, Wieand HA et al. (1993) Combined doxorubicin and alpha-interferon therapy of advanced hepatocellular carcinoma. Cancer 71: 2187–2190

    Article  PubMed  CAS  Google Scholar 

  47. Order SE, Stillwagon GB, Klein JL et al. (1985) Iodine 131 antiferrin, a new treatment modality in hepatoma: a Radiation Therapy Oncology Group study. J Clin Oncol 3: 1573–1582

    PubMed  CAS  Google Scholar 

  48. Sitzmann JU, Order SE, Klein JL, Leichner PK, Fishman EK, Smith GW (1987) Conversion by new treatment modalities of nonresectable to resectable hepatocellular cancer. J Clin Oncol 5: 1566–1573

    PubMed  CAS  Google Scholar 

  49. Order S, Pajak T, Leibel S et al. (1991) A randomized prospective trial comparing full dose chemotherapy to 131I antiferritin: an RTOG study. Int J Radiat Oncol Biol Phys 20: 953–963

    Article  PubMed  CAS  Google Scholar 

  50. Yeung AW, Pang YK, Tsang YC, Wong SW, Leung JS (1993) Short-duration in vitro interleukin-2-activated mononuclear cells for advanced cancer. A Hong Kong Biotherapy pilot study trial. Cancer 71: 3633–3639

    CAS  Google Scholar 

Download references

Authors
  1. C. J. A. Punt
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Innere Klinik und Poliklinik (Tumorforschung) Westdeutsches Tumorzentrum Essen, Universitätsklinikum Essen, Hufelandstraße 55, 45122, Essen, Deutschland

    Siegfried Seeber  & Jochen Schütte  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1995 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Punt, C.J.A. (1995). Hepatozelluläres Karzinom. In: Seeber, S., Schütte, J. (eds) Therapiekonzepte Onkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-10494-1_24

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-10494-1_24

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-58586-2

  • Online ISBN: 978-3-662-10494-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation